TECENTRIQ HYBREZA Trademark

Trademark Overview

On Wednesday, March 30, 2022, a trademark application was filed for TECENTRIQ HYBREZA with the United States Patent and Trademark Office. The USPTO has given the TECENTRIQ HYBREZA trademark a serial number of 97338550. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, July 9, 2024. This trademark is owned by Genentech, Inc.. The TECENTRIQ HYBREZA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, applied subcutaneously and containing atezolizumab, for the treatment of oncological disorders and diseases
tecentriq hybreza

General Information

Serial Number97338550
Word MarkTECENTRIQ HYBREZA
Filing DateWednesday, March 30, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, July 9, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 30, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations, applied subcutaneously and containing atezolizumab, for the treatment of oncological disorders and diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 5, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGenentech, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameGenentech, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events

Event DateEvent Description
Thursday, August 25, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, August 25, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, August 25, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, April 2, 2022NEW APPLICATION ENTERED
Tuesday, April 5, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 25, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, October 24, 2022ASSIGNED TO EXAMINER
Tuesday, October 25, 2022NON-FINAL ACTION E-MAILED
Tuesday, October 25, 2022NON-FINAL ACTION WRITTEN
Tuesday, October 25, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 19, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, April 19, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, April 19, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, April 24, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 19, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 20, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 20, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 20, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 10, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 30, 2023PUBLISHED FOR OPPOSITION
Monday, January 8, 2024SOU EXTENSION 1 FILED
Tuesday, May 30, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 25, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, January 8, 2024SOU TEAS EXTENSION RECEIVED
Monday, January 8, 2024SOU EXTENSION 1 GRANTED
Wednesday, January 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 9, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, July 9, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 9, 2024SOU EXTENSION 2 FILED
Tuesday, July 9, 2024SOU EXTENSION 2 GRANTED

Related Keywords

hybreza tecentriq treatment oncological disorders diseases atezolizumab containing preparations applied subcutaneously pharmaceutical